Teleflex Incorporated announced that a new peer-reviewed study in the Nature journal Prostate Cancer and Prostatic Diseases reinforces the position of the UroLift System as the gold standard in minimally invasive surgical treatment (MIST) for benign prostatic hyperplasia (BPH), or enlarged prostate. Retreatment Rates and Postprocedural Complications Are Higher Than Expected After BPH Surgeries: A U.S. Healthcare Claims and Utilization Study is the largest longitudinal healthcare claims study evaluating complication and retreatment rates after BPH treatment with leading surgical and MIST ever conducted, and the only study to include all outpatient sites of service. Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.

However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies. This first-of-its-kind study overcomes these limitations and directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments. Results suggest that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of whether they receive a transurethral resection of the prostate (TURP), GreenLight photoselective vaporization of the prostate (PVP), Rezum water vapor thermal therapy (WVTT) or UroLift?

System prostatic urethral lift (PUL) (5.9% UroLift PUL, 5.3% TURP, 5.3 GreenLight PVP, 6.2% Rezum? WVTT; rates are not statistically different). At five years, retreatment was lowest for TURP (7.0%) and statistically similar between GreenLight?

PVP and the UroLift System (8.9% and 11.6% respectively). The retreatment rate for UroLift? PUL (11.6%) is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift System.

The study also provides a new way to assess and view complications following BPH surgery, defined as a ?return procedure? in an outpatient setting. Under this definition, at one-year procedural complications were lowest following the UroLift System (15%) and highest following Rezum WVTT (26%).

The average time to the first complication was the longest for the UroLift PUL.